ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Myriad Genetics Inc

Myriad Genetics Inc (MYGN)

4,425
0,035
( 0,80% )
Mis à jour : 21:05:10

Myriad Genetics Inc (MYGN) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
4,425
( 0,80% )
Prix Achat
4,42
Prix Vente
4,43
Volume échangé
505 926
4,315 Fourchette du Jour 4,50
3,53 Plage de 52 semaines 8,59
Cap du marché
Clôture Veille
4,39
Ouverture
4,42
Dernière Transaction
11
@
4.43
Dernière heure de transaction
21:05:19
Volume financier
US$ 2 226 938
VWAP
4,4017
Volume moyen (3 m)
US$ 1 919 148
Actions en circulation
94 448 210
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
-1,06
Bénéfice par action (BPA)
-4,29
Chiffre d'affairess (LTM)
829M
Bénéfice net (LTM)
-399,9M

À propos de Myriad Genetics Inc

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRA... Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah. Show more

Secteur
Healthcare
Industrie
Medical Diagnostics & Screening
Site Web
Siège social
Salt Lake City, United States
Fondé
1991
Myriad Genetics Inc est coté dans le secteur Healthcare de la NASDAQ avec le ticker MYGN. Le dernier cours de clôture d'Myriad Genetics était de US$4,39. Au cours de la dernière année, les actions de Myriad Genetics ont été négociées dans une fourchette de prix de US$ 3,53 à US$ 8,59.

Myriad Genetics compte actuellement 94 448 210 actions en circulation. La capitalisation boursière d'Myriad Genetics est de US$417,93 million. Myriad Genetics a un ratio cours/bénéfice (ratio PE) de -1.06.

MYGN Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.2054.857819905214.224.7754.11516258464.45502573CS
40.2255.357142857144.24.7753.5318492934.00443031CS
12-0.165-3.594771241834.595.363.5315721004.36577447CS
26-2.635-37.32294617567.067.3953.5313768354.85761331CS
52-0.765-14.73988439315.198.593.5314240055.57891331CS
156-18.845-80.984099699223.2729.33.53109635211.18943805CS
260-25.265-85.095991916529.6936.95473.5388539314.47191779CS

MYGN - Frequently Asked Questions (FAQ)

What is the current Myriad Genetics Inc share price?
The current share price of Myriad Genetics Inc is US$ 4,425
How many Myriad Genetics Inc shares are in issue?
Myriad Genetics Inc has 94 448 210 shares in issue
What is the market cap of Myriad Genetics Inc?
The market capitalisation of Myriad Genetics Inc is USD 417,93M
What is the 1 year trading range for Myriad Genetics Inc share price?
Myriad Genetics Inc has traded in the range of US$ 3,53 to US$ 8,59 during the past year
What is the PE ratio of Myriad Genetics Inc?
The price to earnings ratio of Myriad Genetics Inc is -1,06
What is the cash to sales ratio of Myriad Genetics Inc?
The cash to sales ratio of Myriad Genetics Inc is 0,52
What is the registered address of Myriad Genetics Inc?
The registered address for Myriad Genetics Inc is 322 North 2200 West, Salt Lake City, Utah, 84116
What is the Myriad Genetics Inc website address?
The website address for Myriad Genetics Inc is www.myriad.com
Which industry sector does Myriad Genetics Inc operate in?
Myriad Genetics Inc operates in the Medical Diagnostics & Screening sector

MYGN Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock